In the current environment of excess liquidity, "c

In the current environment of excess liquidity, "crazy" company valuations and rising global health problems (obesity, diabetes, cancer, viruses) it is beyond my comprehension that Generex can't get traction of any kind (as far as we know).

Here is a company that is trying to address multiple global health problems, has positive long term test data, has an FDA approved product (Exellagen), has a $535 Million appraisal for NGIO, got a $5 Million advance from China for the Complete Vaccine development and, and, and. Unfortunately, the market currently thinks this is only worth less than $10 Million, which is only $5 Million more than when we went dark. Something is just not adding up...

NuGenerex Family of Companies
NuGenerex Immuno-Oncology (Li-Key Vaccine Technology) <<$535 Million Valuation>>
NuGenerex Health (Health Mgmt Services)
NuGenerex Regenerative Products (Excellagen, ECMH Rectal Solution)
NuGenerex Diagnostics (RAPID 1-2-3 HEMA EXPRESS/CASSETTE)
NuGenerex Therapeutics (Oral-lyn, RapidMist)

https://generex.com/nugenerex-family-companies/